MR studies assess effects of lifelong differences in Lp(a) in general populations, but trials assess effects of short-term reductions in Lp(a) in high-risk participants.53 Therefore, results of MR studies of Lp(a) may not directly anticipate the effects of treatment in Lp(a)-lowering trials, especially for composite outcomes (including stroke and CHD), where the proportions of IS subtypes differ between East Asian and European individuals. The gene discussed is LPA; the disease is Stroke.